Trial
NCT03095612
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Karyopharm Therapeutics Inc
Condition
Non-small Cell Lung Cancer
Intervention
Selinexor
Why stopped
Funding Sponsor no longer supporting study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-13